梅琪, 袁牧, 钱景瑜, 刘若宇, 谭玉林. 肝动脉化疗栓塞术联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的安全性及临床疗效观察[J]. 蚌埠医学院学报, 2024, 49(1): 51-54. DOI: 10.13898/j.cnki.issn.1000-2200.2024.01.011
    引用本文: 梅琪, 袁牧, 钱景瑜, 刘若宇, 谭玉林. 肝动脉化疗栓塞术联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的安全性及临床疗效观察[J]. 蚌埠医学院学报, 2024, 49(1): 51-54. DOI: 10.13898/j.cnki.issn.1000-2200.2024.01.011
    MEI Qi, YUAN Mu, QIAN Jingyu, LIU Ruoyu, TAN Yulin. Safety and clinical efficacy of TACE combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma[J]. Journal of Bengbu Medical College, 2024, 49(1): 51-54. DOI: 10.13898/j.cnki.issn.1000-2200.2024.01.011
    Citation: MEI Qi, YUAN Mu, QIAN Jingyu, LIU Ruoyu, TAN Yulin. Safety and clinical efficacy of TACE combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma[J]. Journal of Bengbu Medical College, 2024, 49(1): 51-54. DOI: 10.13898/j.cnki.issn.1000-2200.2024.01.011

    肝动脉化疗栓塞术联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的安全性及临床疗效观察

    Safety and clinical efficacy of TACE combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma

    • 摘要:
      目的探讨肝动脉化疗栓塞术(TACE)联合卡瑞利珠及阿帕替尼治疗中晚期肝癌的临床疗效。
      方法回顾性分析中晚期肝癌病人40例的临床资料,观察组20例行TACE联合卡瑞利珠及阿帕替尼治疗,对照组20例行TACE联合阿帕替尼治疗。分析2组近、远期疗效及不良反应发生情况。
      结果治疗3个月后复查肝脏增强CT或MRI,观察组客观缓解率为50.0%(10/20),高于对照组的20.0%(4/20)(P<0.05);观察组疾病控制率为85.0%(17/20),与对照组的60.0%(12/20)差异无统计学意义(P>0.05)。随访6~16个月,生存分析显示,观察组无进展生存期均值和中位无进展生存期分别为9.49、8.00个月,对照组分别为7.33、6.00个月,2组差异有统计学意义(P<0.05)。病人常见不良反应包括继发性高血压、手足综合征、肝肾功能损害、骨髓抑制、心脏毒性等,均经药物减量及对症治疗缓解。
      结论TACE联合卡瑞利珠及阿帕替尼治疗中晚期肝癌安全可控,可有效延长病人生存期,值得临床推广。

       

      Abstract:
      ObjectiveTo study the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma.
      MethodsThe clinical data of 40 patients with middle-advanced hepatocellular carcinoma were retrospectively analyzed.The observation group (20 patients) was treated with TACE combined with camrelizumab and apatinib, and the control group (20 patients) was treated with TACE combined with apatinib.The short and long-term efficacy and adverse reactions were analyzed.
      ResultsAfter 3 months of treatment, liver enhanced CT or MRI was reviewed.The objective remission rate of the observation group was 50.0% (10/20), which was higher than that of the control group (20.0% (4/20) (P < 0.05);the disease control rate in the observation group was 85.0% (17/20), which had no significant difference compared with 60.0% (12/20) in the control group (P>0.05).Follow up for 6-16 months, survival analysis showed that the average progression free survival, mean and median progression free survival in the observation group were 9.49 and 8.00 months, and those in the control group were 7.33 and 6.00 months, the difference between the two groups was statistically significant (P < 0.05).Common adverse reactions in patients included secondary hypertension, hand-foot syndrome, liver and kidney dysfunction, bone marrow suppression, cardiotoxicity, etc., which could be alleviated by reduction and symptomatic treatment.
      ConclusionsTACE combined with camrelizumab and apatinib on middle-advanced hepatocellular carcinoma is safe and controllable, which can effectively prolong the survival period of patients, and it is worthy of clinical promotion.

       

    /

    返回文章
    返回